2. Academic Validation
  3. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors

Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors

  • Eur J Med Chem. 2019 Nov 1;181:111552. doi: 10.1016/j.ejmech.2019.07.055.
Huiqiang Wei 1,  Yuqing Duan 1,  Wenfeng Gou 1,  Jie Cui 2,  Hongxin Ning 1,  Deguan Li 1,  Yong Qin 3,  Qiang Liu 4,  Yiliang Li 5
Affiliations

Affiliations

  • 1 Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.
  • 2 Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
  • 3 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: yongqin@mdanderson.org.
  • 4 Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China. Electronic address: liuqiang@irm-cams.ac.cn.
  • 5 Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China. Electronic address: liyiliang@irm-cams.ac.cn.
PMID: 31387063 DOI: 10.1016/j.ejmech.2019.07.055
Abstract

Tyrosine kinase inhibitors (TKIs) have achieved substantial clinical effects for Cancer treatment while causing a number of adverse effects. Since hypoxia is an intrinsic difference between solid tumor and healthy tissues, one strategy to overcome the adverse effects of TKIs is to enhance the specificity of anti-tumor activity by selectively targeting hypoxic region of tumors. Herein, we designed and synthesized a series of novel 4-anilinoquinazoline derivatives by introducing 3-nitro-1,2,4-triazole group to the side chain of vandetanib with modification of aniline moiety. Lead compounds, 10a and 10g, exhibited potent inhibitory activity against EGFR and VEGFR-2 kinase. Moreover, these two compounds were shown to enhance anti-proliferative activities on A549 and H446 cells under hypoxic conditions compared to vandetanib and dramatically down-regulate VEGF gene expression. In vivo studies confirmed that 10a and 10g not only inhibited tumor growth in A549 xenografts of BALB/c-nu mice but also significantly reduce toxicity associated with weight loss compared to vandetanib. These results suggest that EGFR/VEGFR-2 dual inhibitors, 10a and 10g, emerged as potential hypoxia-selective anti-tumor drugs with less toxicity for inhibiting in vitro and in vivo models of non-small cell lung Cancer cells.

Keywords

3-Nitro-1,2,4-triazole; EGFR; Hypoxia; Tyrosine kinase inhibitor; VEGFR-2; Vandetanib.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z